ArticleScientific reports2025
The central lymph node dissection using carbon nanoparticle in transoral vestibular approach endoscopic thyroid surgery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of transoral endoscopic thyroidectomy vestibular approach of papillary thyroid carcinoma: a network meta-analysis.Frontiers in oncology · 2026Pooled it
- Application of the novel tracer mitoxantrone hydrochloride in lymph node visualization during lateral neck dissection for thyroid carcinoma.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This research seeks to explore the application value of carbon nanoparticle (CN) in transoral endoscopic thyroidectomy vestibular approach (TOETVA) with the goal of providing more reliable clinical evidence for minimally invasive treatment of thyroid cancer.A total of 110 patients with differentiated thyroid cancer (DTC) met the inclusion and exclusion criteria from September 2019 to January 2020. They were divided into an experimental group (TOETVA group) of 80 patients and a control group (OT group) of 30 patients based on their cosmetic preferences. All patients were treated with CN during surgery, and the surgeon actively selected lymph nodes and sent them separately for examination according to < 5 mm (small) and ≥ 5 mm (large), recording the number of row retrieved lymph nodes (RRLN). Routine medical examination was conducted to report the number of retrieved lymph nodes (RLN) and positive central lymph nodes (PLNs) detected one week after surgery. The positive rate (PR) of lymph nodes and the proportion of lymph node positive individuals were calculated. Compared with the control group, there was no significant difference between the experimental group and the control group in the proportion of RRLN, RLN, PLN, PR, and lymph node positivity. The differences in the number of lymph nodes of the same group: small lymph nodes have more RRLN and RLN than large lymph nodes, and the difference is statistically significant. In the experimental group, RRLN is larger than RLN, the difference is statistically significant. There is a slight difference between the control group and the experimental group, RRLN is generally higher than RLN. The lymph node clearance effect of TOETVA and OT is basically consistent. The use of CN can improve the detection rate of small lymph nodes in TOETVA, and it is recommended to use CN during the procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.